Pharmascience Inc. v. Meda AB et al - Nov 16, 2021 - Part 2
SSean ProuseNov 16, 2021 at 3:39 pm18min
S
12:54Speaker 1
Do we have counsel with a son that was spared? Okay, recording in progress was my result. Thank you. I'll come back Misha. Go My name is Chip. Um, I would like to start by turning it turning out one of the productions you looked at with counsel this morning, and it is exhibit eight, PMS 136. Just take a moment here to get our share screen rolling. And, and you spoke this morning about this document, but I just want to take a look at the section that says launch assumptions. And in there's the launch at reg approval estimated as of April 14, then there's a reference to could be first or second to market. So at the time, you're anticipating the potential for generic competition.
S
14:02Speaker 2
It's a possibility because there are no patents on their register. We don't have visibility to other activity competitive activity.
S
14:09Speaker 1
And if we can turn up PMS Production Production 135 Or sorry, 137. My apologies. And I don't believe you went to this one this morning. But do you recognize this document Ms. Ship?
S
14:35Speaker 2
I do. It's called commercial evaluation form. It's completed, it's filled out before product goes to the commercial stage.
S
14:44Speaker 1
Thank you and I'd like to mark this as the next exhibit. I believe it might actually be our first one.
Unknown Speaker
What what is what's the FC number?
Processing audio...